Figure 5.

TPX2 silencing inhibited the proliferation through activation of IGFBP3 in pancreas cancer cells. (A) Expression of the IGFBP-3 protein was analyzed by western blotting in KLM1, KP4, and Panc1 cells. These cells were divided into an untreated group, an electroporation-only group, Control siRNA-treated group, and TPX2 siRNAs-treated groups (TPX2 siRNA-1, TPX2 siRNA-2, and TPX2 siRNA-3). β-actin was used as an internal loading control. (B) Effects of TPX2 siRNA treatment on IGFBP3 mRNA expression were determined by real-time RT-PCR in KLM-1 cells (left), KP4 cells (central), and Panc1 cells(right). The expression levels are shown relative to the levels detected in untreated cells. (C) Cell proliferation was assessed in KLM-1 cells using the WST-1 cell proliferation assay. The cells were untreated, transfected with IGFBP3 siRNA and Control siRNA, transfected with TPX2 siRNA and Control siRNA, or transfected with IGFBP3 siRNA and TPX2 siRNA. The time points were 0 and 48 h after the transfection. The data are shown relative to the zero time point. Each point represents the mean of eight replicate wells. No treatment, ; IGFBP3 siRNA and Control siRNA, ; TPX2 siRNA and Control siRNA, ; IGFBP3 siRNA and TPX2 siRNA, . TPX2, targeting protein for Xklp2; IGFBP3, insulin-like growth factor-binding protein-3.